Eli Lilly and Company

Equities

LLY

US5324571083

Real-time Estimate Cboe BZX Other stock markets 02:21:58 2025-12-08 pm EST			5-day change	1st Jan Change
993.88 ^USD	-1.63%		-6.11%	+28.65%

11:16am	Carolyn Bertozzi returns to Lilly board of directors	RE
10:38am	Structure Therapeutics Weight-Loss Pill Achieves 11-15 Percent Reduction in Phase 2 Trial - BN	FW

Transcript : Eli Lilly and Company Presents at Citi Annual Global Healthcare Conference 2025, Dec-02-2025 10

Published on 12/02/2025 at 01:35 pm EST

S&P Capital IQ

Presenter Speech
Geoffrey Meacham (Analysts)

Day 1. We're thrilled today to -- my name is Geoff Meacham. I'm the senior biopharma analyst, and my team is in the audience as well. So we're thrilled

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Eli Lilly and Company

11:16am	Carolyn Bertozzi returns to Lilly board of directors	RE
10:38am	Structure Therapeutics Weight-Loss Pill Achieves 11-15 Percent Reduction in Phase 2 Trial - BN	FW
09:30am	Weight-loss drug developers line up to tap lucrative market as competition heats up	RE
09:37am	Why the Fed's Next Move Matters More Than Markets Admit
10:51am	Structure's obesity pill shows up to 11.3% weight loss in study, shares double	RE
08:08am	Eli Lilly Says Phase 3 Data Shows Jaypirca Meets Primary Endpoint in Blood, Lymph Node Cancer Trial	MT
07:54am	Goldman Sachs Adjusts Price Target on Eli Lilly and Co. to $1,145 From $951, Maintains Buy Rating	MT
06:33am	Eli Lilly, Pfizer Feature in China's Commercial Insurance Innovative Drug Catalog	MT
06:16am	Hutchmed drugs stay on NRDL; Tazverik added to new insurance list	AN
05:22am	Eli Lilly's Mounjaro enters China's insurance system – putting pressure on competitors	FW
04:23am	Eli Lilly's Mounjaro added to China's state insurance list for diabetes treatment	RE
Dec. 07	Lilly's Jaypirca met primary endpoint in head-to-head phase 3 study versus Imbruvica	RE
Dec. 07	Eli Lilly, Pfizer Secure Inclusion in Chinese Private Health Insurance Catalog	MT
Dec. 05	India's Healthify eyes more weight-loss drugmaker tie-ups after Novo Nordisk pact	RE
Dec. 04	Novo Nordisk gears up for Ozempic launch in India, sources say	RE
Dec. 04	BMO Capital Adjusts PT on Eli Lilly and Company to $1,200 From $1,100, Maintains Outperform Rating	MT
Dec. 04	Novo Nordisk to Launch Ozempic in India in Coming Weeks - Reuters	FW
Dec. 03	Details of failed studies cast pall on Novo Nordisk's GLP-1 as Alzheimer's treatment	RE
Dec. 03	Eli Lilly and Company Announces U.S. Food and Drug Administration Approves Expanded Indication for Lilly's Jaypirca (Pirtobrutinib, 100 Mg & 50 Mg Tablets)	CI
Dec. 03	Eli Lilly Says FDA Expands Jaypirca Label in Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma	MT
Dec. 03	Eli Lilly Gets Expanded FDA Approval for Cancer Drug Jaypirca	DJ
Dec. 03	Novo Nordisk gears up for December Ozempic launch in India, sources say	RE
Dec. 03	FDA grants traditional approval to pirtobrutinib	RE
Dec. 03	Excelsior Sciences announced that it has received $70 million in funding from a group of investors	CI
Dec. 03	Alnylam Pharmaceuticals Announces Changes to Board of Directors	CI